IDELVION offers powerful bleed protection
IN PROPHYLAXIS: IDELVION delivers zero bleeds regardless of dosing schedule
When dosed every 7 or 14 days, IDELVION had a zero median annualized spontaneous bleeding rate (AsBR).
When dosed at 14 days, IDELVION had an interquartile range, or IQR, of 0 to 1 bleed (IQR at 7 days was 0 to 0). IQR looks at the middle 50% of people in a clinical study and is used as a more accurate measure of expected range.
“Since I've been infusing with IDELVION, I've had no bleeds.”
-John, on the bleed protection IDELVION gives him
Watch John's story
ON DEMAND: A single dose effectively treats bleeds and offers extended protection—high and sustained Factor IX (FIX) levels for more than 14 days1
A majority of bleeds resolved within 1–2 infusions:
- 94% of bleeds resolved within 1 infusion
- 99% of bleeds resolved within 1–2 infusions
IN SURGERY: IDELVION offers effective bleed protection
of rated surgeries were graded as “excellent” or “good” for bleed control three days after surgery
“I switched to IDELVION because it offered me greater protection. Before surgery, we had several conversations to decide the right dosing.”
-Tony, on switching to IDELVION and having ankle replacement surgery
Watch Tony's story
See what Factor IX levels with 14-day dosing look like
Is it time for a Factor IX switch? Get the information you need
*Average FIX levels with 7-day dosing over 92 weeks in clincal trials.
References: 1. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. doi:10.1182/blood-2012-05-429688. 2. Data on file. Available from CSL Behring as DOF IDL-002.